Flow cytometry analysis also confirmed a decreased proportion of CD4+CD25+CD127− Treg cells in MPR tumor lesions, consistent with the negative association of Tregs to the clinical response to neoadjuvant chemoimmunotherapy (Fig. 5A). The gene discussed is CD4; the disease is neoplasm.